Literature DB >> 2753914

Nigexine, a phospholipase A2 from cobra venom with cytotoxic properties not related to esterase activity. Purification, amino acid sequence, and biological properties.

S Chwetzoff1, S Tsunasawa, F Sakiyama, A Ménez.   

Abstract

The venoms of the Naja species are known to be cytotoxic. This toxicity has been attributed to the presence of small nonenzymatic polypeptides of 60 amino acid residues, designated as cardiotoxins or cytotoxins. We investigated the cytotoxic potency of Naja nigricollis venom fractions and isolated another type of cytotoxic component which is even more potent than cardiotoxins. This cytotoxic compound, which was designated as nigexine, was purified to homogeneity and its amino acid sequence was determined. Nigexine is a basic phospholipase A2 consisting of a single chain of 118 amino acids. A detailed investigation of the cytotoxic effects on epithelial FL cells, C-13T neuroblastoma cells, and promyelocytic leukemia HL 60 cells revealed that nigexine not only altered cell viability but also prevented cell proliferation. This is a property that was specific to nigexine since other phospholipases A2 from various sources had no detectable cytotoxic activity. The cytotoxic activity of nigexine was not dependent on the presence of divalent cations, unlike its enzymatic activity. In particular, the cytotoxic activity of nigexine was identical in the presence or absence of either 2 mM Ca2+ or Sr2+, or 6 mM EDTA. We also present evidence based on chemical modifications that cytotoxic activity was not correlated with enzymatic activity. Thus, modification with parabromophenacyl bromide totally abolished the enzymatic activity of nigexine, which nevertheless retained 6-20% of the cytotoxicity of native nigexine. Conversely, treatment with cyanogen bromide gave a compound that retained 7% of the enzymatic activity of the parent molecule but was devoid of detectable cytotoxicity.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2753914

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  16 in total

1.  Determination of the amino acid sequence of a new phospholipase A(2) (MIDCA1) isolated from Micrurus dumerilii carinicauda venom.

Authors:  Cháriston A Dal Belo; Marcos H Toyama; Daniela de O Toyama; Sergio Marangoni; F B Moreno; Benildo S Cavada; Marcos D Fontana; S Hyslop; E M Carneiro; Antonio C Boschero
Journal:  Protein J       Date:  2005-04       Impact factor: 2.371

2.  In vitro comparison of cytotoxic effects of crotoxin against three human tumors and a normal human epidermal keratinocyte cell line.

Authors:  C J Rudd; L J Viskatis; J C Vidal; M A Etcheverry
Journal:  Invest New Drugs       Date:  1994       Impact factor: 3.850

3.  Neurotoxicity and other pharmacological activities of the snake venom phospholipase A2 OS2: the N-terminal region is more important than enzymatic activity.

Authors:  Morgane Rouault; Lachlan D Rash; Pierre Escoubas; Eric Boilard; James Bollinger; Bruno Lomonte; Thomas Maurin; Carole Guillaume; Stéphane Canaan; Christiane Deregnaucourt; Joseph Schrével; Alain Doglio; José María Gutiérrez; Michel Lazdunski; Michael H Gelb; Gérard Lambeau
Journal:  Biochemistry       Date:  2006-05-09       Impact factor: 3.162

4.  Secreted phospholipases A(2), a new class of HIV inhibitors that block virus entry into host cells.

Authors:  D Fenard; G Lambeau; E Valentin; J C Lefebvre; M Lazdunski; A Doglio
Journal:  J Clin Invest       Date:  1999-09       Impact factor: 14.808

5.  Swine as a model of skin inflammation. Phospholipase A2-induced inflammation.

Authors:  X Nair; D Nettleton; D Clever; K M Tramposch; S Ghosh; R C Franson
Journal:  Inflammation       Date:  1993-04       Impact factor: 4.092

6.  Cytotoxicity of crotoxin on murine erythroleukemia cells in vitro.

Authors:  R E Corin; L J Viskatis; J C Vidal; M A Etcheverry
Journal:  Invest New Drugs       Date:  1993-02       Impact factor: 3.850

7.  VRCTC-310--a novel compound of purified animal toxins separates antitumor efficacy from neurotoxicity.

Authors:  R A Newman; J C Vidal; L J Viskatis; J Johnson; M A Etcheverry
Journal:  Invest New Drugs       Date:  1993 May-Aug       Impact factor: 3.850

8.  Cloning and identification of a complete cDNA coding for a bactericidal and antitumoral acidic phospholipase A2 from Bothrops jararacussu venom.

Authors:  Patrícia G Roberto; Simone Kashima; Silvana Marcussi; José O Pereira; Spartaco Astolfi-Filho; Auro Nomizo; José R Giglio; Marcos R M Fontes; Andreimar M Soares; Suzelei C França
Journal:  Protein J       Date:  2004-05       Impact factor: 2.371

Review 9.  Antitumoral activity of snake venom proteins: new trends in cancer therapy.

Authors:  Leonardo A Calderon; Juliana C Sobrinho; Kayena D Zaqueo; Andrea A de Moura; Amy N Grabner; Maurício V Mazzi; Silvana Marcussi; Auro Nomizo; Carla F C Fernandes; Juliana P Zuliani; Bruna M A Carvalho; Saulo L da Silva; Rodrigo G Stábeli; Andreimar M Soares
Journal:  Biomed Res Int       Date:  2014-02-13       Impact factor: 3.411

Review 10.  Insights into the antiviral activity of phospholipases A2 (PLA2s) from snake venoms.

Authors:  S C Teixeira; B C Borges; V Q Oliveira; L S Carregosa; L A Bastos; I A Santos; A C G Jardim; F F Melo; L M Freitas; V M Rodrigues; D S Lopes
Journal:  Int J Biol Macromol       Date:  2020-07-19       Impact factor: 6.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.